Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil.

Trial Profile

CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Latrepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms CONCERT
  • Sponsors Medivation

Most Recent Events

  • 10 Mar 2012 This trial has been completed in Germany, France, Sweden and Italy as reported by European Clinical Trials Database (Parent trial: EudraCT2008-008005-21).
  • 17 Jan 2012 Results published in a Medivation and Pfizer media release.
  • 17 Jan 2012 The open label extension study in Alzheimer's disease will be terminated, according to a media release from Medivation and Pfizer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top